US FDA advisory committee members split on whether Sanofi and Lexicon Pharmaceuticals Inc.'s proposed type 1 diabetes treatment sotagliflozin should be approved amid questions about how to manage the risk of diabetic ketoacidosis.
The 8-8 vote by the Endocrinologic and Metabolic Drugs Advisory Committee Jan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?